Last reviewed · How we verify
NCT03613428
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
Phase 1, PHASE2 trial testing Ruxolitinib in Acute T Cell Leukemia in 12 participants. Status unknown.
30 December 2020
Quick facts
| Lead sponsor | Sichuan University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 December 2018 |
| Primary completion | 30 December 2020 |
| Estimated completion | 30 March 2021 |
Drugs / interventions tested
- Ruxolitinib (RUXOLITINIB) — full drug profile →
- Vincristine (vincristine) — full drug profile →
- Prednisone (prednisone) — full drug profile →
Conditions studied
- Acute T Cell Leukemia — all drugs for Acute T Cell Leukemia →
Sponsor
Sichuan University
Who can join
Adults 13 to 75, any sex, with Acute T Cell Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute lymphocytic leukemia (ETP-ALL). Once determined, the purpose of this study will be to determine the efficacy of ruxolitinib in combination with LVP in patients with R/R ETP-ALL.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.
Follini E, Marchesini M, Roti G. · · 2019 · cited 52× · PMID 31226848 · DOI 10.3390/ijms20123021 -
The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.
Fattizzo B, Rosa J, Giannotta JA, Baldini L, et al · · 2020 · cited 45× · PMID 32185137 · DOI 10.3389/fonc.2020.00273 -
Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.
Castaneda Puglianini O, Papadantonakis N. · · 2020 · cited 23× · PMID 32733662 · DOI 10.1177/2040620720929475 -
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. · · 2021 · cited 22× · PMID 34073410 · DOI 10.3390/cancers13112611 -
Inflammation as a driver of hematological malignancies.
Saluja S, Bansal I, Bhardwaj R, Beg MS, et al · · 2024 · cited 16× · PMID 38571491 · DOI 10.3389/fonc.2024.1347402 -
Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets.
Genescà E, la Starza R. · · 2022 · cited 15× · PMID 35454781 · DOI 10.3390/cancers14081873 -
Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick.
Tarantini F, Cumbo C, Anelli L, Zagaria A, et al · · 2021 · cited 8× · PMID 34930475 · DOI 10.1186/s40364-021-00347-z -
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.
Parri E, Kuusanmäki H, Bulanova D, Mustjoki S, et al · · 2021 · cited 8× · PMID 33792631 · DOI 10.1182/bloodadvances.2020003300
Verify or expand the search:
- PubMed search for NCT03613428
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ruxolitinib
Trials testing the same drug.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
- NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
Other Sichuan University trials
Trials by the same sponsor.
- NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
- NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03613428 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan University
- Last refreshed: 3 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613428.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing